AstraZeneca (LON:AZN) Receives “Buy” Rating from Berenberg Bank

Berenberg Bank reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on Monday,Digital Look reports. The brokerage currently has a GBX 140 ($1.75) target price on the biopharmaceutical company’s stock.

A number of other research analysts also recently issued reports on AZN. JPMorgan Chase & Co. restated an “overweight” rating and issued a £140 ($175.15) price target on shares of AstraZeneca in a research report on Friday, November 22nd. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, AstraZeneca currently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 7,935.67 ($99.28).

AstraZeneca Trading Down 0.4 %

Shares of AZN stock traded down GBX 44 ($0.55) on Monday, reaching £106.68 ($133.47). 1,807,867 shares of the stock were exchanged, compared to its average volume of 2,434,591. The stock has a market cap of £165.35 billion, a P/E ratio of 3,386.67, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97. The firm has a 50 day moving average of £105.36 and a two-hundred day moving average of £116.94. AstraZeneca has a 1-year low of GBX 9,461 ($118.37) and a 1-year high of £133.88 ($167.50).

Insider Transactions at AstraZeneca

In other AstraZeneca news, insider Pascal Soriot purchased 20,000 shares of the stock in a transaction on Thursday, November 14th. The stock was bought at an average cost of £102.03 ($127.65) per share, for a total transaction of £2,040,600 ($2,552,983.86). Also, insider Tony Mok acquired 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The stock was bought at an average cost of £126.80 ($158.64) per share, for a total transaction of £190,200 ($237,958.21). 0.04% of the stock is currently owned by corporate insiders.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.